Self-administered hyaluronidase-facilitated subcutaneous immunoglobulin therapy in complicated primary antibody deficiencies.
Hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIg) is a new immunoglobulin product for replacement therapy in patients with primary antibody deficiencies (PAD). The pre-administration of recombinant human hyaluronidase associated with 10% immunoglobulin allowed the infusion of larger (up to 600 ml) amounts of immunoglobulin at a single infusion site, enabling patients to receive the necessary treatment in a single monthly dose. Here, we report the effectiveness and the tolerability of fSCIg in patients with severe PAD-related comorbidities: refractory autoimmune thrombocytopenia; systemic granulomatous disease; severe enteropathy, and Type I diabetes. We conclude that fSCIg could be a feasible option to improve the adherence to replacement therapy also by patients with severe PAD.
['Danieli|Maria Giovanna|MG|', 'Pulvirenti|Federica|F|', 'Rocchi|Valeria|V|', 'Morariu|Ramona|R|', 'Quinti|Isabella|I|']
D000328:Adult D000361:Agammaglobulinemia D017074:Common Variable Immunodeficiency D003922:Diabetes Mellitus, Type 1 D005260:Female D040181:Genetic Diseases, X-Linked D006105:Granulomatous Disease, Chronic D006801:Humans D006821:Hyaluronoglucosaminidase D007116:Immunization, Passive D055104:Infusions, Subcutaneous D008286:Malabsorption Syndromes D055118:Medication Adherence D008875:Middle Aged D016553:Purpura, Thrombocytopenic, Idiopathic D012646:Self Administration
subcutaneous immunoglobulin thrombocytopenia granulomatous disease enteropathy X-linked agammaglobulinemia common variable immunodeficiency cytopenias facilitated subcutaneous immunoglobulin immunomodulation, intravenous immunoglobulin